3 hours ago
1
Kitsawet Saethao
- GSK plc (NYSE:GSK) said that the US FDA is currently reviewing an application to expand the use of Arexvy, an adjuvanted vaccine against respiratory syncytial virus (RSV).
- This expansion aims to include adults aged 18 to 49 who are considered
English (US) ·